Ceftriaxone and Rebound effect - a phase IV clinical study of FDA data

Summary:

Rebound effect is reported as a side effect among people who take Ceftriaxone (ceftriaxone sodium), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Metformin, and have Interstitial lung disease.

The phase IV clinical study analyzes which people have Rebound effect when taking Ceftriaxone. It is created by eHealthMe based on reports of 40,872 people who have side effects when taking Ceftriaxone from the FDA, and is updated regularly.

What is Ceftriaxone?

Ceftriaxone has active ingredients of ceftriaxone sodium. It is often used in typhoid fever. eHealthMe is studying from 40,991 Ceftriaxone users. Check the latest studies of Ceftriaxone.

What is Rebound effect?

Rebound effect (take-back effect) is found to be associated with 369 drugs and 569 conditions by eHealthMe. Check the latest studies of Rebound effect.

On Aug, 12, 2026

40,872 people reported to have side effects when taking Ceftriaxone.
Among them, 20 people (0.05%) have Rebound effect.

Among these 20 people:

How long have people been on Ceftriaxone when they have Rebound effect? *

What is the gender of people who have Rebound effect when taking Ceftriaxone? *

female: 11.11 %
male: 88.89 %

What is the age of people who have Rebound effect when taking Ceftriaxone? *

What are other drugs people take besides Ceftriaxone? *

What are other side effects people have besides Rebound effect? *

Drug Ineffective: 8 people, 40.00%
Visual Acuity Reduced (reduced clearness of vision): 6 people, 30.00%
Lacrimal Gland Enlargement: 5 people, 25.00%
Acute Febrile Neutrophilic Dermatosis (skin disease characterized by the sudden onset of fever, leukocytosis, and tender): 5 people, 25.00%
Blindness: 5 people, 25.00%
Disease Progression: 5 people, 25.00%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 3 people, 15.00%
Chorioretinal Atrophy (damaged retina and choroid part of eye): 3 people, 15.00%
Fever: 3 people, 15.00%
Febrile Neutropenia (fever with reduced white blood cells): 2 people, 10.00%

What are the existing conditions these people have? *

Acute Febrile Neutrophilic Dermatosis (skin disease characterized by the sudden onset of fever, leukocytosis, and tender): 4 people, 20.00%
Type 2 Diabetes: 4 people, 20.00%
Sinusitis (inflammation of sinus): 4 people, 20.00%
High Blood Pressure: 4 people, 20.00%
Scleritis (inflammation of sclera): 4 people, 20.00%
Interstitial Lung Disease: 4 people, 20.00%
Fever: 3 people, 15.00%
Urinary Tract Infection: 3 people, 15.00%
Chorioretinal Atrophy (damaged retina and choroid part of eye): 3 people, 15.00%
Infection: 3 people, 15.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftriaxone and have Rebound effect?

- Check whether Rebound effect is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ceftriaxone:

Ceftriaxone (40,991 reports)

Rebound effect treatments and more:

Rebound effect (8,859 reports)

Browse all side effects of Ceftriaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rebound effect:

Rebound effect (369 drugs)

Browse all the conditions that are associated with Rebound effect:

Rebound effect (569 conditions)

Related publications that referenced our studies

Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .
Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium (the active ingredients of Ceftriaxone) and Ceftriaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.